Advertisement
Screener

4D Molecular Therapeutics, Inc. (FDMT) Cash Flow Breakdown

2.8 / 5 stars · 68/120 Roast Me

4D Molecular Therapeutics, Inc. Cash Flow Breakdown

Cash flow breakdown shows where 4D Molecular Therapeutics, Inc.'s cash came from and where it went: from running the business, from investing (buying or selling equipment, companies and investments) and from financing (borrowing, paying back loans, buying back shares, paying dividends). One row per year or quarter. A minus sign means cash went out. Financing is shown line by line: buybacks, dividends, debt paid back, new debt and the rest. All amounts are the filed figures for that period.

  • Fiscal year ended 2025-12-31: from running the business, $109.08M went out.
  • Fiscal year ended 2025-12-31: from investing, $92.97M went out.
  • Fiscal year ended 2025-12-31: from financing, $112.96M came in.
  • Fiscal year ended 2025-12-31: change in cash, $89.09M went out.

A minus sign means cash went out. * = worked out from the filed year-to-date figures (hover to see how); greyed = already counted inside another line.

Each year (12 month)

Fiscal year endRunning the businessFrom investingNew shares soldNot split outChange in cash
2025-12-31-$109.08M-$92.97M$112.96M*-$89.09M
2024-12-31-$134.59M-$302.44M$337.25M*-$99.77M
2023-12-31-$75.79M$115.72M$156.83M*$196.76M
2022-12-31-$86.69M-$17.05M$0.00$3.08M*-$100.65M
2021-12-31-$69.13M-$172.68M$114.30M$3.79M*-$123.72M
2020-12-31-$50.91M-$1.00M$205.66M$73.33M*$227.07M
2019-12-31-$36.71M-$3.20M$75.00K-$2.27M*-$42.11M

Each quarter (3 month)

Quarter endRunning the businessFrom investingNew shares soldNot split outChange in cash
2026-06-30-$70.00M*$25.54M*$42.34M*
2026-03-31-$68.13M$68.89M$11.48M*$12.25M
2025-12-31$28.55M*-$128.85M*$111.98M*
2025-09-30-$46.50M*$17.78M*
2025-06-30-$43.38M*-$13.85M*$862.00K*
2025-03-31-$47.76M$31.95M-$15.81M
2024-12-31-$45.86M*$7.06M*$601.00K*
2024-09-30-$29.39M*$27.30M*$568.00K*
2024-06-30-$30.24M*-$73.54M*$17.25M*
2024-03-31-$29.09M-$263.26M$3.11M$315.72M*$26.49M
2023-12-31-$24.65M*-$6.68M*$4.76M*
2023-09-30-$1.17M*$29.98M*$10.56M*
2023-06-30-$22.07M*$49.29M*$130.52M*
2023-03-31-$27.91M$43.13M$1.42M$9.58M*$26.22M
2022-12-31-$22.21M*-$35.78M*$2.05M*
2022-09-30-$21.02M*$15.37M*
2022-06-30-$19.90M*$57.47M*
2022-03-31-$23.55M-$54.11M$875.00K-$77.03M
2021-12-31-$21.84M*-$32.29M*$116.14M*
2021-09-30-$15.72M*-$139.01M*$1.98M*
2021-06-30-$16.20M*-$737.00K*$820.00K*
2021-03-31-$15.37M-$642.00K-$847.00K*-$16.86M
2020-12-31-$17.50M*-$508.00K*$205.98M*
2020-09-30-$13.37M*$349.00K*$900.00K*
2020-06-30-$6.17M*-$120.00K*$72.49M*
2020-03-31-$13.87M-$721.00K$5.00K-$14.98M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Solid Biosciences Inc. (SLDB)United States$0.802B-5.07
Aura Biosciences, Inc. (AURA)United States$0.639B-5.61
Attovia Therapeutics, Inc. (ATTO)United States$0.828B
Candel Therapeutics, Inc. (CADL)United States$0.885B-8.86
Sana Biotechnology, Inc. (SANA)United States$0.886B-4.92
Allogene Therapeutics, Inc. (ALLO)United States$0.574B-4.33
Prime Medicine, Inc. (PRME)United States$0.557B-3.54
Autolus Therapeutics plc (AUTL)$0.506B-1.52
Odyssey Therapeutics, Inc. (ODTX)United States$0.960B
Entera Bio Ltd. (ENTX)$0.485B